CAESAREA, Israel, Oct. 3, 2017 /PRNewswire/ -- DarioHealth Corp.
(NASDAQ: DRIO), a leading global digital health company with mobile
health and big data solutions, today announced it expands its
global reach with a successful launch into the German market,
making its smart diabetes platform available for the first time in
the EU's largest market, both by population and GDP.
With this launch, DarioHealth is now commercially available in 9
countries around the world. DarioHealth will operate its
direct-to-consumer channel, leveraging its in-depth knowledge from
other markets to provide new opportunities for more than 8 million
Germans living with diabetes.
Erez Raphael, Chairman and CEO of
DarioHealth, commented, "Our technology can help guide consumers to
analyze and personalize their diabetes treatment in effort to
increase better clinical outcomes. We've received tremendous
positive feedback about the Dario smart diabetes solution and we
look forward to providing the German market with an unrivaled
method for self-diabetes management.
"From a business perspective, this is a very big achievement for
us. We've successfully expanded our international market presence,
allowing us to capitalize on the most cost-effective markets as we
bring personalized healthcare management to diabetes and
pre-diabetes patients around the world."
DarioHealth expects the launch into the German market to help
the Company reach its Q4 revenue goals and FY2017 annual
milestones. Diabetes is on the rise in Germany, with an estimated ten percent of its
82 million population living with this chronic disease.
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital health company
serving tens of thousands of users with dynamic mobile health
solutions. We believe people deserve the best tools to manage their
treatment, and harnessing big data, we have developed a unique way
for our users to analyze and personalize their diabetes management.
With our smart diabetes solution, users have direct access to track
and monitor all facets of diabetes, without having the disease slow
them down. The acclaimed Dario™ Blood Glucose Monitoring System
all-in-one blood glucose meter and native smartphone app gives
users an unrivaled method for self-diabetes management. DarioHealth
is headquartered in Caesarea,
Israel with a regional office in Burlington, Massachusetts. For more
information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company describes
the expectations of the launch into the German market, it is using
forward-looking statements. Readers are cautioned that certain
important factors may affect the Company's actual results and could
cause such results to differ materially from any forward-looking
statements that may be made in this news release. Factors that may
affect the Company's results include, but are not limited to,
regulatory approvals, product demand, market acceptance, impact of
competitive products and prices, product development,
commercialization or technological difficulties, the success or
failure of negotiations and trade, legal, social and economic
risks, and the risks associated with the adequacy of existing cash
resources. Additional factors that could cause or contribute to
differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth Corporate and Media Contact
Shmuel Herschberg
Marketing Director
shmuel@mydario.com
+1-914-775-5548
DarioHealth Investor Relations Contact
Hayden IR
Stephen Hart
DRIO@HaydenIR.com
+1-917-658-7878
View original
content:http://www.prnewswire.com/news-releases/dariohealth-launches-into-the-german-diabetes-market-300529699.html
SOURCE DarioHealth Corp.